Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- HIV / AIDs
- Biotechnology
- Pharmaceuticals
- Disease
- Delivery
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5352
License Grant
Board of the University hereby grants to Licensee a royalty-bearing, exclusive license under to manufacture, have manufactured, use and/or sell products related to following technology.
License Property
o (MDA REF UTSC060-1) (CIP of UTSC060) entitled 'Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome'
o U.S. Patent No. 5,128,319 entitled 'Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome', (MDA REF UTSC234)
o MDA REF UTSC242 entitled 'Methods and Compositions for the Priming of Specific Cytotoxic T-Lymphocyte Response'
o MDA REF UTSC267 (Divisional of UTSC234) 'Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome'
o MDA REF UTSC305 entitled 'Compositions and Methods for Eliciting Immune or Anti-Infective Responses'
o MDA REF UTSC331 entitled 'CD4 Peptides for Binding to Viral Envelope Proteins'
o MDA REF UTSC381 entitled 'Peptides for Inhibitiing the Infection of Target Cells by Lentiviruses'
Field of Use
The Licensee acquired a license to seven patents and patent applications related to technology for HIV/AIDS therapy and prevention.
IPSCIO Record ID: 26363
License Grant
The Company entered into a worldwide exclusive patent license agreement with the Licensor, government public health organization, concerning composition of matter for BlockAide/CR.
License Property
BlockAide/CR&#-3884; is a peptide-based drug that is intended to work by blocking viral entry and infection of human immune system cells.
The patents covering a peptide product, known as BlockAide, for the treatment and prevention of HIV.
Field of Use
The rights granted apply to the medical industry relating to human infections.
IPSCIO Record ID: 203504
License Grant
Licensor grants an exclusive (even as to Licensor), license under the Patent Assets and Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, market and sell and otherwise dispose of Compound and Product, including any Improvements thereto, in the Territory.
License Property
The Licensed products contain the compound. The Compound shall mean a condensation polymer of an aromatic sulfonic acid and an aldehyde or a pharmaceutically acceptable salt or prodrug thereof or a derivative, homolog, or analog thereof.
Field of Use
The Compound is for a candidate topical microbicide used to prevent infection by the human immunodeficiency virus (HIV) and other sexually transmitted pathogens.
IPSCIO Record ID: 27353
License Grant
The University hereby grants to Licensee exclusive licenses under Patent Rights to make, use, sell, offer for sale, and import Patent Products in the Field and to practice the Patent Method in the Field; Applications of Coated Nanocrystalline Particles (Invention), useful in the development of vaccine adjuvants, virus vaccine constructs, drug delivery systems, and a red blood cell surrogate.
License Property
U.S. Patent No. 5,178,882 entitled 'Viral Decoy Vaccine, U.S. Patent No. 5,219,577 'Biologically Active Composition Having a Nanocrystalline Core', U.S. Patent No. 5,306,508 entitled 'Red Blood Cell Surrogate', U.S. Patent No. 5,334,394 entitled 'Human Immunodeficiency Virus Decoy'
U.S. Patent No. 5,460,830 entitled 'Biochemically Active Agents for Chemical Catalysis and Cell Receptor Activation', U.S. Patent No. 5,460,831 entitled 'Targeted Transfection Nanoparticles', U.S. Patent No. 5,462,750 entitled 'Biologically Active Compositions Having a Nanocrystalline Core', U.S. Patent No. 5,462,751 entitled 'Biological and Pharmaceutical Agents Having a Nanomeric Biodegradable Core' and U.S. Patent No. 5,464,634 entitled 'Red Blood Cell Surrogate'.
Field of Use
'Field' means vaccine Adjuvant, Virus Vaccine Construct, Drug Delivery System and Red Blood Cell Surrogate.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
